
Pfizer, Moderna COVID-19 vaccines show no safety concerns during first month of rollout, CDC says
Fox News
No concerning safety issues were associated with either the Pfizer and BioNTech or Moderna coronavirus vaccines during the first month of shots, the Centers for Disease Control and Prevention (CDC) reported Friday
The agency did note "rare cases" of anaphylaxis among both Pfizer and Moderna vaccine recipients, but that it was not outside of the range of those seen with other vaccines. "The occurrence of anaphylaxis after receipt of COVID-19 vaccines during the analytic period, 4.5 cases per million doses administered, is within the range reported after receipt of inactivated influenza vaccine (1.4 per million), pneumococcal polysaccharide vaccine (2.5 per million), and live attenuated herpes zoster vaccine (9.6 per million); effective treatments for anaphylaxis exist (6)," the report said. The agency also said adverse reactions to the Pfizer vaccine were more frequently reported after receiving the second dose than the first, but that information pertaining to Moderna's second dose was not yet available due to dosing intervals.More Related News













